# Edith A. Perez

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/edith-a-perez/

## Facts

| Field | Value |
| --- | --- |
| Citations | 59,576 |
| Field | Breast Cancer Treatment Studies |
| h-index | 95 |
| i10-index | 321 |
| Last Known Institution | Jacksonville College |
| OpenAlex ID | https://openalex.org/A5065306642 |
| ORCID iD | https://orcid.org/0000-0002-5037-6677 |
| Works | 663 |

## Researcher papers

- [Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer](https://scholariq.org/papers/trastuzumab-plus-adjuvant-chemotherapy-for-operable-her2-positive-breast-cancer/)
- [The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014](https://scholariq.org/papers/the-evaluation-of-tumor-infiltrating-lymphocytes-tils-in-breast-cancer/)
- [Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer](https://scholariq.org/papers/paclitaxel-plus-bevacizumab-versus-paclitaxel-alone-for-metastatic-breast-cancer/)
- [A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer](https://scholariq.org/papers/a-randomized-trial-of-letrozole-in-postmenopausal-women-after-five-years-of/)
- [Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741](https://scholariq.org/papers/randomized-trial-of-dose-dense-versus-conventionally-scheduled-and-sequential/)
- [Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial](https://scholariq.org/papers/prognostic-and-predictive-value-of-the-21-gene-recurrence-score-assay-in/)
- [RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer](https://scholariq.org/papers/ribbon-1-randomized-double-blind-placebo-controlled-phase-iii-trial-of/)
- [Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100](https://scholariq.org/papers/association-of-vascular-endothelial-growth-factor-and-vascular-endothelial/)
- [Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial](https://scholariq.org/papers/pictilisib-for-oestrogen-receptor-positive-aromatase-inhibitor-resistant/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Estrogen and related hormone effects](https://scholariq.org/topics/estrogen-and-related-hormone-effects/)

## Researcher university

- [Jacksonville College](https://scholariq.org/institutions/jacksonville-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.